Craving and addictive potential of esketamine as side effects?
Laura OrsoliniVirginio SalviUmberto VolpePublished in: Expert opinion on drug safety (2022)
Esketamine showed great efficacy and safety in treating TRD and MDD with acute suicidal ideation or behavior. Our clinical experience demonstrated the presence of an additive potential, which has been favorably managed with slow esketamine de-titration and combination with bupropion. However, literature so far published is scant and shows contradictory findings. Therefore, it is crucial to promptly detect and manage craving symptomatology in esketamine-treated TRD patients. In our experience, the use of bupropion to counteract craving and addictive symptoms was proven to be effective and safe.
Keyphrases
- newly diagnosed
- end stage renal disease
- ejection fraction
- systematic review
- liver failure
- prognostic factors
- major depressive disorder
- human health
- risk assessment
- drug induced
- hepatitis b virus
- physical activity
- aortic dissection
- patient reported
- sleep quality
- acute respiratory distress syndrome
- mechanical ventilation
- alcohol use disorder